Drugs / DTacP
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06184542 | Dec 2023 → Dec 2024 overdue | diphtheria, pertussis, tetanus | Institute of Medical Biology, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07112144 | Jun 2025 → Jun 2032 expected | diphtheria, tetanus | Changchun BCHT Biotechnology Co. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DTacP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07112144 ↗ |
| Modality | Vaccine | “Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine” NCT06184542 ↗ |
| Route | Intramuscular | “All children will receive the injection in the deltoid muscle of the upper arm on Day 0.” NCT06184542 ↗ |